Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Moderna Yönetim

Yönetim kriter kontrolleri 3/4

Moderna's CEO'su Stephane Bancel, Oct2011 tarihinde atandı, in görev süresi 13.58 yıldır. in toplam yıllık tazminatı $ 17.07M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.2% maaş ve 90.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 5.49% ine doğrudan sahiptir ve bu hisseler $ 1.41B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.5 yıl ve 10.4 yıldır.

Anahtar bilgiler

Stephane Bancel

İcra Kurulu Başkanı

US$17.1m

Toplam tazminat

CEO maaş yüzdesi	9.2%
CEO görev süresi	13yrs
CEO sahipliği	5.5%
Yönetim ortalama görev süresi	4.5yrs
Yönetim Kurulu ortalama görev süresi	10.4yrs

Son yönetim güncellemeleri

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30

Recent updates

Moderna: Still Bullish View

Sep 20

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Sep 12

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Aug 26

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Aug 18

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Aug 03

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Apr 22

Moderna: Considering The Cancer Vaccine Angle

Apr 11

Moderna Continues To Build A Pipeline

Apr 03

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Mar 27

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27

Moderna: Counting On Pipeline Too Much

Feb 23

Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World

Feb 16

Moderna: Fade 2025 Outlook

Jan 15

Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 29

CEO Tazminat Analizi

Stephane Bancel'un ücretlendirmesi Moderna'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$6b
Mar 31 2024	n/a	n/a	-US$6b
Dec 31 2023	US$17m	US$2m	-US$5b
Sep 30 2023	n/a	n/a	-US$3b
Jun 30 2023	n/a	n/a	US$1b
Mar 31 2023	n/a	n/a	US$5b
Dec 31 2022	US$19m	US$1m	US$8b
Sep 30 2022	n/a	n/a	US$12b
Jun 30 2022	n/a	n/a	US$14b
Mar 31 2022	n/a	n/a	US$15b
Dec 31 2021	US$18m	US$990k	US$12b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$3b
Mar 31 2021	n/a	n/a	US$598m
Dec 31 2020	US$13m	US$946k	-US$747m
Sep 30 2020	n/a	n/a	-US$597m
Jun 30 2020	n/a	n/a	-US$488m
Mar 31 2020	n/a	n/a	-US$505m
Dec 31 2019	US$9m	US$921k	-US$514m
Sep 30 2019	n/a	n/a	-US$535m
Jun 30 2019	n/a	n/a	-US$499m
Mar 31 2019	n/a	n/a	-US$459m
Dec 31 2018	US$59m	US$863k	-US$402m
Sep 30 2018	n/a	n/a	-US$299m
Jun 30 2018	n/a	n/a	-US$280m
Mar 31 2018	n/a	n/a	-US$266m
Dec 31 2017	US$7m	US$651k	-US$270m

Tazminat ve Piyasa: Stephane 'nin toplam tazminatı ($USD 17.07M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 13.04M ).

Tazminat ve Kazançlar: Stephane 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Stephane Bancel (51 yo)

13yrs

Görev süresi

US$17,068,514

Tazminat

Mr. Stephane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel serves as Interim President of Valera LLC. Mr. Bancel serves as a Special Partner at Flagship Pioneering since F...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephane Bancel	CEO & Director	13yrs	US$17.07m	5.49% $ 1.3b
Stephen Hoge	President	no data	US$7.34m	0.42% $ 96.3m
James Mock	Chief Financial Officer	2.1yrs	US$4.32m	0.0023% $ 527.6k
Shannon Klinger	Chief Legal Officer & Corporate Secretary	3.3yrs	US$4.31m	0.0047% $ 1.1m
Jerh Collins	Chief Technical Operations & Quality Officer	1.8yrs	Veri yok	Veri yok
Brad Miller	Chief Information Officer	1.8yrs	Veri yok	Veri yok
Lavina Talukdar	Senior VP & Head of Investor Relations	5.5yrs	Veri yok	Veri yok
Colleen Hussey	Senior Director of Corporate Communications	no data	Veri yok	Veri yok
Tracey Franklin	Chief Human Resources Officer	5yrs	Veri yok	Veri yok
Melanie Ivarsson	Chief Development Officer	4.8yrs	Veri yok	Veri yok
Dave Johnson	Chief Data & AI Officer	no data	Veri yok	Veri yok
Charbel Haber	Senior VP & Head of Global Regulatory Science	4.5yrs	Veri yok	Veri yok

4.5yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: MRNA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephane Bancel	CEO & Director	13.6yrs	US$17.07m	5.49% $ 1.3b
Noubar Afeyan	Co-Founder	14.8yrs	US$663.52k	0.58% $ 133.9m
Elizabeth Tallett	Independent Director	4.3yrs	US$481.27k	0.00018% $ 41.7k
Robert Langer	Member of Scientific Advisory Board	no data	US$461.27k	2.99% $ 692.9m
Scott Canute	Member of Technology Advisory Board	10.4yrs	Veri yok	Veri yok
Elizabeth Nabel	Independent Director	3.6yrs	US$476.25k	0.00055% $ 127.3k
Fred Regnier	Member of Technology Advisory Board	10.4yrs	Veri yok	Veri yok
Francois Nader	Independent Non Executive Director	4.8yrs	US$481.27k	0.0054% $ 1.2m
James Swartz	Member of Technology Advisory Board	10.4yrs	Veri yok	Veri yok
Ulrich von Andrian-Werburg	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jack Szostak	Chairman of Scientific Advisory Board	10.4yrs	Veri yok	Veri yok
John Aunins	Member of Technology Advisory Board	10.4yrs	Veri yok	Veri yok

10.4yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MRNA 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.4 yıldır).

Moderna Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna, Inc. Announces Board Changes

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Insufficient new directors

Recent updates

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna: Still Bullish View

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Price target decreased by 16% to US$105

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Consensus revenue estimates fall by 21%

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

New minor risk - Share price stability

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

Moderna, Inc. Announces Board Changes

Co-Founder notifies of intention to sell stock

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna: Really Strong Competition

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Co-Founder notifies of intention to sell stock

Moment Of Truth Approaches For Moderna's RSV Vaccine

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

Moderna Q1: A Promising Pipeline Is Undervalued

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Moderna: Considering The Cancer Vaccine Angle

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna Continues To Build A Pipeline

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Co-Founder notifies of intention to sell stock

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

President notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Moderna: Counting On Pipeline Too Much

Moderna, Inc., Annual General Meeting, May 06, 2024

Consensus EPS estimates fall by 12%

CEO & Director recently sold US$2.3m worth of stock

Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

President notifies of intention to sell stock

Moderna: Fade 2025 Outlook

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

President notifies of intention to sell stock

Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi